Health economic impact of first-pass success among patients with acute ischemic stroke treated with mechanical thrombectomy: a United States and European perspective by Zaidat, Osama O et al.
  1Zaidat OO, et al. J NeuroIntervent Surg 2020;0:1–7. doi:10.1136/neurintsurg-2020-016930
Original research
Health economic impact of first- pass success among 
patients with acute ischemic stroke treated with 
mechanical thrombectomy: a United States and 
European perspective
Osama O Zaidat   ,1 Marc Ribo   ,2,3 Heinrich Paul Mattle,4 Jeffrey L Saver,5 
Hormozd Bozorgchami,6 Albert J Yoo,7 Alexandra Ehm,8 Emilie Kottenmeier,9 
Heather L Cameron,10 Rana A Qadeer,10 Tommy Andersson11,12
Ischemic stroke
To cite: Zaidat OO, Ribo M, 
Mattle HP, et al. 
J NeuroIntervent Surg Epub 
ahead of print: [please 
include Day Month Year]. 
doi:10.1136/
neurintsurg-2020-016930
 ► Additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
neurintsurg- 2020- 016930).
For numbered affiliations see 
end of article.
Correspondence to
Dr Osama O Zaidat, Department 
of Neuroscience, Mercy Saint 
Vincent Medical Center, Toledo, 
OH 43608, USA;  OOZaidat@ 
Mercy. com
Received 4 October 2020
Revised 23 November 2020
Accepted 24 November 2020
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
ABSTRACT
Background First- pass effect (FPE), restoring complete 
or near complete reperfusion (modified Thrombolysis in 
Cerebral Infarction (mTICI) 2c-3) in a single pass, is an 
independent predictor for good functional outcomes in 
the endovascular treatment of acute ischemic stroke. The 
economic implications of achieving FPE have not been 
assessed.
Objective To assess the economic impact of achieving 
complete or near complete reperfusion after the first 
pass.
Methods Post hoc analyses were conducted using 
ARISE II study data. The target population consisted of 
patients in whom mTICI 2c–3 was achieved, stratified 
into two groups: (1) mTICI 2c–3 achieved after the first 
pass (FPE group) or (2) after multiple passes (non- FPE 
group). Baseline characteristics, clinical outcomes, 
and healthcare resource use were compared between 
groups. Costs from peer- reviewed literature were applied 
to assess cost consequences from the perspectives of 
the United States (USA), France, Germany, Italy, Spain, 
Sweden, and United Kingdom (UK).
Results Among patients who achieved mTICI 2c–3 
(n=172), FPE was achieved in 53% (n=91). A higher 
proportion of patients in the FPE group reached good 
functional outcomes (90- day modified Rankin Scale 
score 0–2 80.46% vs 61.04%, p<0.01). The patients 
in the FPE group had a shorter mean length of stay 
(6.10 vs 9.48 days, p<0.01) and required only a single 
stent retriever, whereas 35% of patients in the non- FPE 
group required at least one additional device. Driven 
by improvement in clinical outcomes, the FPE group 
had lower procedural/hospitalization- related (24–
33% reduction) and annual care (11–27% reduction) 
costs across all countries.
Conclusions FPE resulted in improved clinical 
outcomes, translating into lower healthcare resource use 
and lower estimated costs.
INTRODUCTION
Worldwide, stroke is the leading cause of mortality 
and disability with a substantial economic impact.1 
The direct and indirect costs of stroke were esti-
mated at US$33.9 billion in the United States (USA) 
in 2012–2013.2 Similarly, in Europe, the annual 
economic burden was estimated to be €45 billion 
in the European Union (EU) alone in 2015.3 
Approximately 87% of all strokes are acute isch-
emic strokes4 and 24% to 38% of acute ischemic 
strokes are caused by large vessel occlusions, which 
are associated with additional costs.5 A study from 
the USA demonstrated that total costs per patient 
were higher for patients with large vessel occlu-
sions than for those without large vessel occlusions 
(US$18 815 vs US$15 174).6
Complete reperfusion of brain tissue is the 
primary goal in treatment of acute ischemic stroke. 
Rapid revascularization is vital as reduced time 
from symptom onset to revascularization is strongly 
correlated with improved clinical and functional 
outcomes.7 8 Complete revascularization with 
mechanical thrombectomy, a cost- effective treat-
ment for patients with acute stroke, might require 
multiple passes, which prolongs procedure time and 
increases the risk of arterial endothelial injury.9 10 
Research suggests that first- pass effect (FPE)—that 
is, restoring complete or near complete reperfu-
sion (modified Thrombolysis in Cerebral Infarction 
(mTICI) 2c–3) in a single pass, is an independent 
predictor of good functional outcome (modified 
Rankin Scale (mRS) score 0–2).9 Although the clin-
ical benefits of achieving complete or near complete 
reperfusion after the first pass have been investi-
gated, the potential economic benefit has not been 
assessed.
The objective of this analysis was to assess the 
economic impact of achieving complete or near 
complete reperfusion after the first pass, FPE, 
as compared with the need for multiple passes 
to achieve the same level of reperfusion. Clinical 
outcomes were derived from patient- level data of 
the ARISE II (Analysis of Revascularization in Isch-
emic Stroke with EmboTrap) study, and the analysis 
was done from the perspective of various health-
care systems (USA, France, Germany, Italy, Spain, 
Sweden, and United Kingdom (UK)).
METHODS
Data source
Post hoc analyses were conducted using patient- 
level data from the ARISE II study, a prospective 
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single- arm international multicenter clinical trial, investigating 
the efficacy and safety of the EmboTrap device (Cerenovus, 
Irvine, California, USA) in 227 treated patients. Although the 
EmboTrap device was used in all procedures as a first- line treat-
ment, the technique used in the ARISE II study was based on 
investigator’s choice (ie, the physicians established an appro-
priate treatment plan based on the subject’s medical condition 
and available diagnostic screening procedures); specific recom-
mendations were not provided for the use of intermediate cath-
eters (data as to whether the stent retriever was 'engulfed' or 
'corked' are not available); and pump suction was not used. 
Details of the ARISE II study are provided in Zaidat et al 2018.11
Target population and comparators
Aligned with the ARISE II publication,11 FPE was defined as 
complete or near complete reperfusion (mTICI 2c–3) after the 
first pass with the EmboTrap device. As such, the target popu-
lation consisted of patients in whom mTICI 2c–3 was achieved 
(n=172) in the ARISE II population (patients in whom mTICI 
2c–3 was not achieved (n=55) were excluded from the analyses 
to avoid potential selection bias). The target population was then 
stratified into two groups: (1) patients in whom mTICI 2c–3 was 
achieved after the first pass (FPE group) or (2) after multiple 
passes (non- FPE group). The two groups were defined based on 
the core laboratory adjudicated mTICI scores measured after the 
first pass (ie, total number of passes did not affect categorization).
Primary analyses
Primary analyses were conducted in two steps. First, baseline 
characteristics, clinical outcomes, and healthcare resource use 
were evaluated for each group (ie, FPE and non- FPE) using data 
from the ARISE II study. Second, cost data from peer- reviewed 
literature were applied to assess cost consequences using a deter-
ministic approach from two different perspectives, provider and 
payer.
Baseline characteristics
Baseline characteristics were compared between the FPE and 
non- FPE groups to examine the risk of systematic bias and 
confounders (table 1).
Clinical outcomes
The following clinical outcomes were assessed: core laboratory 
adjudicated mTICI score after each pass and at the end of the 
procedure, 90- day mRS score (categorized into good (mRS 
Table 1 Baseline characteristics for the FPE and non- FPE groups
Variable FPE (n=91) Non- FPE (n=81) P Value*
Demographics
  Age, mean (SD) 68.4 (11.9) 67.7 (14.3) 0.70
  Sex, male, n (%) 43 (47.3%) 33 (40.7%) 0.39
Vascular risk factors, n (%)
  Hypertension 66 (72.5%) 57 (70.4%) 0.75
  Atrial fibrillation 32 (35.2%) 38 (46.9%) 0.12
  Diabetes mellitus 16 (17.6%) 17 (21.0%) 0.57
  Dyslipidemia 38 (41.8%) 37 (45.7%) 0.61
  Smoking 19 (20.9%) 21 (25.9%) 0.43
  Previous MI/CAD 23 (25.3%) 11 (13.6%) 0.06
  Previous stroke 16 (17.6%) 13 (16.0%) 0.79
Clinical presentation, median (IQR)
  Baseline NIHSS score 16 (11–19) 16 (13–20) 0.40
  Baseline systolic BP, mm Hg† 144 (130–158) 148 (134–158) 0.31
  Baseline diastolic BP, mm Hg† 80 (70–91) 81 (72–93) 0.29
Occlusion location, n (%)
  Internal carotid artery 14 (15.4%) 13 (16.0%) 0.90
  M1 middle cerebral artery 48 (52.7%) 46 (56.8%) 0.60
  M2 middle cerebral artery 22 (24.2%) 20 (24.7%) 0.94
  Posterior 7 (7.7%) 2 (2.5%) 0.17
Procedural factors
  Time from onset to puncture (min), median (IQR) 214 (161–263) 220 (153–270) 0.54
  General anesthesia, n (%) 33 (36.3%) 25 (30.9%) 0.46
  IV tPA use, n (%) 59 (64.8%) 56 (69.1%) 0.55
  Balloon guide catheter use, n (%) 71 (78.0%) 60 (74.1%) 0.54
  Intermediate catheter use, n (%) 20 (22.0%) 41 (50.6%) <0.01
*P values presented for t- test beside means, Wilcoxon rank sum (Mann- Whitney) test beside medians, and chi- square or Fisher’s exact tests beside proportions.
†Four patients missing data for systolic and diastolic BP.
BP, blood pressure; CAD, coronary artery disease; FPE, first- pass effect; IQR, interquartile range; IV, intravenous; MI, myocardial infarction; NIHSS, National Institutes of Health 
Stroke Scale; SD, standard deviation; tPA, tissue plasminogen activator.
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score 0–2) and excellent (mRS score 0–1) functional outcomes), 
90- day mortality, occurrence of symptomatic intracranial hemor-
rhage within 24 hours postprocedure based on the Heidelberg 
Bleeding Classification, embolization into new territory, and 
discharge status (home, acute care facility, or extended care) 
assessed at 7 days post- procedure.
Healthcare resource use
Procedural/hospitalization- related resources, associated with the 
initial stroke, were compared between the FPE and non- FPE 
groups (total hospital length of stay (LOS), days in the inten-
sive care unit, standard bed days, and devices used during the 
procedure).
Economic outcomes
Cost consequences were compared between the FPE and non- 
FPE groups from the perspective of healthcare systems in the 
USA, France, Germany, Italy, Spain, Sweden, and UK with two 
separate time horizons (procedural/hospitalization- related and 
annual care in the first year after stroke, details provided below). 
Clinical and healthcare resource use was obtained from the 
ARISE II study, and country- specific healthcare resource costs 
were obtained from peer- reviewed literature and public market 
research reports, which were validated by clinical experts in 
interviews. All costs were reported as 2020 currencies and 2020 
United States dollars (US$), and were inflated using country- 
specific inflation indices if required. The Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) statement 
was used for the reporting of the economic analyses.12
The procedural/hospitalization- related economic impact 
was calculated in the following steps. First, the procedural/
hospitalization- related healthcare resource use was obtained for 
patients in the FPE and non- FPE groups from the ARISE II study. 
Second, country- specific costs valuing those resources were taken 
from peer- reviewed literature (LOS costs) and public market 
research reports (device costs).13–21 The resources captured in 
the LOS costs were similar across the literature (online supple-
mental table I). Third, total costs per patient from a provider 
perspective in the acute care setting were calculated.
The costs per patient arising during the first year after the 
stroke from a payer perspective were also calculated in three 
steps. First, proportions of patients achieving each mRS score (ie, 
mRS 0 to 6) at 90 days were obtained for each group. Second, 
country- specific annual care costs, based on 90- day mRS score, 
were obtained from the literature but were not available for 
Germany and Spain.16 22–25 The resources captured in the annual 
care costs mainly focused on direct healthcare resources (online 
supplemental table I). Third, total costs per patient arising from 
a payer perspective were calculated.
Sensitivity analyses
To test the robustness of the results, univariate sensitivity 
analyses varying key input parameters were conducted. These 
included analyses with two alternative definitions of FPE11 26: (1) 
'FPE (mTICI 3)', defined as achieving mTICI 3 after the first pass 
and (2) 'FPE (mTICI 2b–3)', defined as achieving mTICI 2b–3 
after the first pass. Accordingly, based on the chosen definition 
of FPE, the target population was also adjusted (eg, patients in 
whom mTICI 3 was not achieved were excluded from the anal-
yses when the definition of FPE was changed to FPE (mTICI 3)). 
Two additional parameters were also varied: (1) total LOS was 
varied within its interquartile range (IQR) since this parameter 
was not normally distributed and (2) country- specific healthcare 
resource costs were increased/decreased by 20% as confidence 
intervals for these costs were not reported in the literature. A 
hypothetical cost- efficiency analysis was also conducted using a 
cohort of 200 cases, where the procedural/hospitalization- related 
impact of using two devices with variable rates of achieving FPE 
was compared. In this analysis, it was assumed that one device 
achieved FPE in an additional 5% of the cases as compared with 
the other device.
Statistical analyses
Continuous variables were described using the mean or median 
and standard deviation (SD) or IQR, while categorical variables 
were described using the number of observations and propor-
tions. Statistical significance testing was based on a p value of 
<0.05 for the following tests: t- test and Wilcoxon rank- sum 
(Mann- Whitney) test for continuous variables and chi- square or 
Fisher’s exact test for categorical variables. All statistical analyses 
of the ARISE II data were performed using Stata 15 (StataCorp, 
College Station, Texas, USA).
RESULTS
In the ARISE II study, complete or near complete reperfusion 
(ie, mTICI 2c–3) was achieved in 76% of the patients (n=172); 
among these patients, FPE was observed in 53% (n=91) (online 
supplemental figure I). Baseline characteristics were mostly 
balanced between the FPE and non- FPE groups. Notably, inter-
mediate catheter use was lower in the FPE group than in the 
non- FPE group (22.0% vs 50.6%, p<0.01; table 1).
A significantly higher proportion of patients in the FPE 
group achieved good (mRS 0–2, 80.46% vs 61.04%, p<0.01) 
or excellent (mRS 0–1, 63.22% vs 46.75%, p=0.03) func-
tional outcomes as compared with patients in the non- FPE 
group (table 2 and online supplemental figure II). Although the 
proportion of patients who died or had symptomatic intracra-
nial hemorrhage were lower in the FPE group, the differences 
were not statistically significant. The proportion of patients 
who had an embolization into a new territory was significantly 
lower in the FPE group (2.20% vs 11.11%, p=0.03; table 2). 
The proportions of patients discharged to their home or to 
acute/extended care facilities (skilled nursing home, rehabilita-
tion), respectively, were similar between the FPE and non- FPE 
groups (43.53% and 44.74% discharged to home and 56.47% 
and 55.26% discharged to acute/extended care facilities, respec-
tively, p=0.88).
Patients in the FPE group required only a single EmboTrap 
device, whereas 35% of patients in the non- FPE group required 
at least one additional device. The patients in the FPE group 
were also discharged significantly earlier with a shorter mean 
LOS (6.10 (IQR=3.00–8.00) vs 9.48 (IQR=3.00–11.00) days, 
p<0.01). Patients in the FPE group had significantly fewer mean 
number of days spent in a standard bed (3.05 (IQR=0.00–5.00) 
vs 6.13 (IQR=1.00–8.00), p<0.01), whereas the mean number 
of days spent in the intensive care unit was similar between the 
two groups (3.39 (IQR=2.00–4.00) vs 3.58 (IQR=2.00–4.00), 
p=0.70; table 2).
Subsequent to the improvements in clinical outcomes and 
lower healthcare resource use during the acute care phase, the 
economic cost assessment accordingly estimated lower costs 
for the FPE group. When the acute care costs arising within 
the hospital (ie, procedural/hospitalization- related costs) were 
assessed, achieving FPE led to potential per- patient cost savings in 
every country studied (US$6575 for the USA, €1560 (US$1833) 
for France, €2202 (US$2587) for Germany, €2901 (US$3409) 
for Italy, €4548 (US$5343) for Spain, Kr 29 468 (US$3364) 
copyright.














4 Zaidat OO, et al. J NeuroIntervent Surg 2020;0:1–7. doi:10.1136/neurintsurg-2020-016930
Ischemic stroke
for Sweden, and £1751 (US$2285) for the UK; table 3, online 
supplemental figure III). Similarly, achieving FPE led to poten-
tial per- patient annual care cost savings in the first year after 
stroke in every country studied (US$4116 for the USA, €2131 
(US$2503) for France, €701 (US$823) for Italy, Kr 13 333 for 
Sweden (US$1522), and £2132 (US$2783) for the UK; table 4, 
online supplemental figure IV).
When the criteria for FPE were defined to be more limited 
(ie, mTICI 3 after the first pass), this FPE was observed in 57% 
(n=67) of the patients who finally achieved mTICI 3 (n=118). 
The FPE (mTICI 3) group was associated with improved clinical 
outcomes and reduced healthcare resource use as compared with 
the non- FPE group, including patients with mTICI 2c reperfu-
sion after first- pass (online supplemental table II). Similar to 
the main analyses, limiting the FPE group to FPE (mTICI 3) led 
to potential per- patient procedural/hospitalization- related and 
annual care cost savings (online supplemental table III). When the 
criteria for FPE were broadened (ie, defined as mTICI 2b–3 after 
the first pass), FPE was seen in 56% (n=117) of the patients who 
finally achieved at least mTICI 2b. Notably, achieving mTICI 
2b–3 after the first pass was also associated with improved clin-
ical outcomes and reduced healthcare resource use and costs 
(online supplemental tables III and IV). Variations of the total 
LOS within the IQR and increasing or decreasing the costs by 
20% did not alter the direction of the results but did change 
the magnitude of the estimated cost savings (online supplemental 
table III).
















  LOS* $9832 €1381 €3096 €3124 €6542 Kr 68 942 £3019
  Devices/methods used $7886 €2325 €1415 €3458 €2709 Kr 26 424 £2416
  Total $17 718 €3706 €4511 €6581 €9252 Kr 95 365 £5435
Non−FPE (n=81)
  LOS* $13 616 €2146 €4811 €4854 €10 167 Kr 89 376 £3955
  Devices/methods used $10 678 €3120 €1902 €4628 €3632 Kr 35 457 £3231
  Total $24 293 €5266 €6713 €9483 €13 799 Kr 124 833 £7186
Difference (2020 currencies) −$6575 −€1560 −€2202 −€2901 −€4548 −Kr 29 468 −£1751
Difference (2020 US$)† −$6575 −$1833 −$2587 −$3409 −$5343 −$3364 −$2285
Numbers may not sum due to rounding.
*Costs for LOS for US, UK, and Sweden were based on total LOS and proportion of standard bed vs intensive care unit days (standard bed and intensive care unit days costed 
separately). Costs for LOS for France, Italy, Spain, and Germany were based on total LOS (separate costs for intensive care unit stay and standard bed days not found in the 
literature; as such, a general cost for LOS was used).
†Exchange rates reported for August 03, 2020, 16:00 UTC were used. The exchange rates were as follows: €1.00=US$1.17, Kr1.00=US$0.11, and £1.00=US$1.31.
FPE, first- pass effect; LOS, length of stay; UTC, coordinated universal time.
Table 2 Clinical and healthcare resource use outcomes for the FPE and non- FPE groups
Outcome FPE (n=91) Non- FPE (n=81) P value*
Clinical outcomes
90- Day mRS score (categorized into good and excellent functional outcomes)†
  Good outcomes (mRS score 0–2), n (%) 70 (80.46%) 47 (61.04%) <0.01
  Excellent outcomes (mRS score 0–1), n (%) 55 (63.22%) 36 (46.75%) 0.03
90- Day mortality,‡ n (%) 5 (5.68%) 11 (13.75%) 0.08
sICH within 24 hours, n (%) 2 (2.20%) 4 (4.94%) 0.42
ENT, n (%) 2 (2.20%) 9 (11.11%) 0.03
Healthcare resource use outcomes
LOS
  Total LOS, mean (IQR)§ 6.10 (3.00–8.00) 9.48 (3.00–11.00) <0.01
  Standard bed days, mean (IQR)¶ 3.05 (0.00–5.00) 6.13 (1.00–8.00) <0.01
  ICU days, mean (IQR)** 3.39 (2.00–4.00) 3.58 (2.00–4.00) 0.70
*P values presented for the following tests: t- test or Wilcoxon rank- sum (Mann- Whitney) test for continuous variables and chi- square or Fisher’s exact test for categorical 
variables.
†Eight patients missing data for 90- day mRS score.
‡Four patients missing data for 90- day mortality.
§Represents the date of discharge minus date of admission to study hospital; seven patients missing data for LOS.
¶Represents the normal ward days; 10 patients missing data for standard bed days.
**Eight patients missing data for ICU days.
ENT, embolization into new territory; FPE, first- pass effect; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay; mRS, modified Rankin Scale; NA, not applicable; 
sICH, symptomatic intracerebral hemorrhage.
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In the hypothetical analysis that applied procedural/
hospitalization- related costs for the FPE versus non- FPE groups 
(eg, for the US analyses, per- patient costs for the FPE and non- 
FPE group were $17 718 and $24 293, respectively) and assessed 
the impact of two devices with variable rates of achieving FPE 
in a cohort of 200 a per year, the device that achieved a 5% 
higher FPE rate led to cost savings of US$65 753 in the USA, 
US$18 328 in France, US$25 868 in Germany, US$34 087 in 
Italy, US$53 433 in Spain, US$33 637 in Sweden, and US$22 847 
in the UK.
DISCUSSION
We assessed the economic impact of achieving FPE in patients 
with acute ischemic stroke from the perspective of healthcare 
systems in the USA, France, Germany, Italy, Spain, Sweden, and 
UK using patient- level data from the ARISE II study and cost 
data from peer- reviewed literature. The results demonstrated 
that patients achieving FPE had improved functional outcomes, 
lower risk for embolization into a new territory, and a faster 
recovery time (shorter LOS). These clinical improvements led to 
reduced procedural/hospitalization- related and annual care costs 
in every country studied. The findings proved to be robust after 
conducting a range of sensitivity analyses that varied key inputs, 
including the definition of FPE.
The clinical findings in this analysis of the ARISE II data are 
supported by previous literature.9 26 Zaidat et al demonstrated 
that patients in the North American Solitaire Stent Retriever 
Acute Stroke (NASA) registry (n=354) with FPE had improved 
functional outcomes (90- day good functional outcome: 55.1% 
vs 31.3%, p<0.01) and reduced mortality (16.3% vs 36.5%, 
p<0.01) as compared with patients without FPE.9 Similarly, a 
study by Nikoubashman with 164 consecutive patients in whom 
mTICI 3 was achieved showed that complete reperfusion after 
the first pass was associated with improved functional outcomes 
(90- day good functional outcome: 62% vs 40%, p=0.013).26 
Additionally, the association between FPE and favorable clinical 
outcome (mRS score at 90 days of 0–2 or equal to pre- stroke 
mRS score) has been shown to be independent of the technique 
used (stent retriever vs aspiration, p=0.29).27
This analysis demonstrated that achieving mTICI 2c–3 after 
the first pass was associated with reduced healthcare resource 
use. Patients in the FPE group required fewer thrombectomy 
devices; the number of devices used to achieve mTICI 2c–3 is 
inevitably linked to the number of passes even though up to three 
attempts with the same device were allowed in the EmboTrap 
instructions for use. Patient recovery was faster for patients with 
FPE as indicated by the significantly shorter total hospital LOS. 
As such, achieving mTICI 2c–3 after the first pass led to poten-
tial per- patient procedural/hospitalization- related cost savings 
in every country studied. Notably, the reductions in healthcare 
resource use and cost savings were driven by the improvements 
in clinical outcomes. An analysis of the GAIN international trial 
demonstrated that LOS in hospital during the first 90 days after 
a stroke was positively associated with 90- day mRS score.28 
Long- term direct healthcare costs of stroke are mainly driven 
by patients who do not achieve functional recovery and their 
degree of disability.29 30 Thus, due to the higher rate of patients 
achieving functional independence in the FPE group, our anal-
ysis showed that patients in the FPE group had lower costs in 
the first year after stroke than those in the non- FPE group. 
These findings are also aligned with a recent Markov model 
that showed that achieving expanded TICI (eTICI) 3 resulted in 
healthcare (US$10 327) and societal (US$20 224) cost savings 
as compared with achieving eTICI 2b among patients with large 
vessel occlusions.31
Rapid revascularization is widely accepted to be strongly 
correlated with improved clinical outcomes.7 8 It might be 
argued that the improvements in clinical outcomes seen in this 
study were not due to FPE per se but due to the prolonged 
time between groin puncture and reperfusion associated with 
multiple passes.26 However, a matched case–control analysis that 
adjusted for time from symptom onset to complete reperfusion 
showed that the occurrence of good functional outcomes was 
almost twice as common among those who achieved complete 
reperfusion after the first pass as compared with those who 
achieved complete reperfusion after multiple passes.26 Addition-
ally, Garcia- Tornel and colleagues reported a linear association 
between the number of passes and good functional outcomes 
among patients who underwent mechanical thrombectomy 
procedures for large vessel occlusion in the anterior circulation 
and achieved recanalization as compared with patients who did 
not achieve recanalization.32 Jindal et al also reported that the 
Table 4 Average per- patient annual care costs, based on 90- day mRS score, for the FPE and non- FPE groups
mRS score
% Achieving mRS score Average costs for annual care/mRS score by country
FPE (n=91) Non- FPE (n=81) US (2020 US$) France (2020 €) Italy (2020 €) Sweden (2020 Kr) UK (2020 £)
0 41.38% 19.48% $12 176 €12 817 €2072 Kr 74 717 £3255
1 21.84% 27.27% $12 538 €12 817 €2437 Kr 98 093 £3829
2 17.24% 14.29% $14 504 €12 817 €2803 Kr 153 609 £4403
3 9.20% 7.79% $24 905 €22 244 €5524 Kr 186 481 £15 666
4 2.30% 11.69% $50 408 €40 144 €7474 Kr 244 084 £21 196
5 2.30% 5.19% $74 108 €40 144 €16 599 Kr 297 096 £34 418
6 5.75% 14.29% – – – – –
Results by country
FPE (n=91) $15 430 €14 203 €2934 Kr 108 413 £5661
Non- FPE (n=81) $19 546 €16 334 €3635 Kr 121 746 £7794
Difference (2020 currencies) −$4116 −€2131 −€701 −Kr 13 333 −£2132
Difference (2020 US$)* −$4116 −$2503 −$823 −$1522 −$2783
Numbers may not sum due to rounding.
*Exchange rates reported for August 03, 2020, 16:00 UTC were used. The exchange rates were as follows: €1.00=US$1.17, Kr1.00=US$0.11, and £1.00=US$1.31.
FPE, first- pass effect; mRS, modified Rankin Scale; UTC, coordinated universal time.
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proportion of patients who achieved good functional outcome 
was inversely related to the number of passes among anterior 
cerebral circulation stroke thrombectomy cases.33 Similarly, 
multivariable analyses from Zaidat et al demonstrated that 
achieving FPE was an independent predictor of good functional 
outcome.9
Although there are factors that might affect the likelihood of 
achieving FPE (eg, factors related to the treating physician such 
as training, settings such as available equipment, and patients 
such as clot composition), recent research has suggested that 
certain techniques involving the combined use of stent retrievers 
and intermediate aspiration catheters could improve recanaliza-
tion rates and the rate of FPE.34 35 Thus it might be beneficial to 
'throw everything in' immediately to improve the likelihood of 
achieving FPE. In this context it might be surprising that the use 
of intermediate catheters was less frequent in the FPE group than 
in the non- FPE group (22.0% vs 50.6%, p<0.01), as several 
published techniques (eg, SAVE, PROTECTPLUS) that incorpo-
rate intermediate catheters report a high percentage of FPE.34 36 
Potential explanations for the higher use of intermediate cath-
eters in the non- FPE versus FPE group include electing to use 
the intermediate catheter after first- pass failure (perhaps, due to 
thrombus composition and/or lack of standardized practices).
Research examining the reasons for improved clinical outcomes 
with FPE is ongoing; current literature suggests that repeated 
thrombectomy passes may be associated with an increased risk 
of vessel injury and distal embolization, which could negatively 
impact clinical outcomes.9 26 Additionally, more passes increase 
the risk of losing embolic fragments into previously unaffected 
territories. This hypothesis is supported by the results of this 
study, which showed that the proportion of patients who had 
embolization into a new territory was significantly lower in 
the FPE group than in the non- FPE group (2.20% vs 11.11%, 
p=0.03). Both distal embolization and embolization into new 
vascular territories damage brain tissue directly and can also 
cut off leptomeningeal collaterals and thus accelerate dying of 
penumbral tissue.
This study has several strengths, including the use of patient- 
level data from a multi- country study to inform the health 
economic analyses, inclusion of several countries in the health 
economic analyses for increased generalizability, and differ-
entiation between acute and annual care costs. Furthermore, 
as compared with previous literature,9 the target population 
for this study excluded patients for whom mTICI 2c–3 was 
not achieved to obtain a homogeneous patient cohort and to 
conduct an unbiased assessment of FPE. However, the find-
ings of this study should be interpreted in the context of the 
following limitations. First, there were limitations in relation to 
the procedural/hospitalization- related and annual care cost data 
used in this analysis, which were obtained from the literature. 
There were differences in resources captured in costs across 
countries and in the patient populations that were assessed in 
the cost literature and in the ARISE II study, respectively.16 23 25 
However, this study used the best available cost estimates, which 
were validated by clinical experts in interviews. Second, it is 
plausible that resource use may vary across countries owing 
to variations in clinical practices. Sensitivity analyses assessing 
differences by region were not feasible due to small sample sizes. 
Third, procedural/hospitalization- related and annual care costs 
were not comprehensive. Analyses assessing the procedural/
hospitalization- related economic impact did not include costs 
for procedure time and intermediate catheters (lower use in the 
FPE group), and analyses assessing the annual care economic 
impact did not include costs for death (ie, mRS score 6), which 
had a lower incidence in the FPE group. Fourthly, the economic 
impact of FPE was assessed in a deterministic analysis (ie, a prob-
abilistic model was not created as we used point estimates from 
one clinical study and costs from the literature, which often did 
not report the associated measures of variability). However, we 
used the best available estimates for all key inputs and conducted 
numerous sensitivity analyses, including those that altered the 
definition of FPE.
CONCLUSIONS
According to our knowledge, this is the first study which assesses 
the health economic impact of FPE. The analysis showed that 
patients in the FPE group had improved clinical outcomes as 
compared with patients in the non- FPE group, which resulted 
in lower healthcare resource use and improved economic 
outcomes. Overall, the findings indicate that the performance 
within the thrombectomy procedure affects both the clinical 
outcome and healthcare spending in the short and long term. 
Thus FPE represents a relevant procedural goal for endovas-
cular treatment of acute ischemic stroke. Moreover, the first- line 
treatment should ideally involve a thrombectomy technique that 
provides the best chance of succeeding in the first pass. Future 
economic studies that obtain clinical and economic data from 
the same data source are required to validate the findings from 
these analyses. Additionally, studies are required to determine 
the factors and techniques/methods that maximize the likelihood 
of achieving FPE.
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